Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (noting a discrepancy with the request metadata which listed "Rein Therapeutics, Inc.") on June 5, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol ALRN. The report addresses corporate governance changes regarding executive officers.
Key Financial Metrics
This filing is a current report regarding personnel changes and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Resignation of CFO: Richard J. Wanstall, the Company's Chief Financial Officer, principal financial officer, and principal accounting officer, resigned effective May 6, 2022.
- Appointment of New Officers: On June 5, 2022, the Board of Directors appointed Manuel Aivado, M.D., Ph.D., the Company's President and Chief Executive Officer, to serve as the new principal financial officer and principal accounting officer.
Management Commentary and Risks
Dr. Aivado, age 52, has served as President, CEO, and a board member since September 2018. The filing explicitly states there are no arrangements or understandings regarding his selection, no family relationships with other directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. No specific risks, contingencies, or unusual items related to financial performance are disclosed in this document.
Investor Verification Checklist
- Verify the correct company name is Aileron Therapeutics, Inc. (ALRN), not Rein Therapeutics, Inc.
- Confirm the effective date of the CFO resignation (May 6, 2022) and the appointment of the new principal financial officer (June 5, 2022).
- Review subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.
- Monitor for the appointment of a dedicated Chief Financial Officer, as the CEO is currently serving in the dual role of principal financial officer.